Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0,87%
1 065,23
+9,15
+0,87%
—1 056,081 055,451 067,221 044,14——
SIXC
Communications
SIXC
Communications
SIXC
+0,37%
609,17
+2,27
+0,37%
—606,90606,90610,73601,25——
SIXE
Energy
SIXE
Energy
SIXE
-1,24%
1 236,17
-15,54
-1,24%
—1 251,711 264,021 267,841 229,38——
SIXI
Industrials
SIXI
Industrials
SIXI
+0,26%
1 725,15
+4,51
+0,26%
—1 720,641 717,521 726,381 702,65——
SIXM
Financials
SIXM
Financials
SIXM
+0,29%
637,83
+1,82
+0,29%
—636,01635,43638,09630,76——
SIXR
Staples
SIXR
Staples
SIXR
-0,91%
854,06
-7,82
-0,91%
—861,88854,93854,93841,82——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0,09%
218,27
+0,19
+0,09%
—218,08218,08218,34215,77——
SIXT
Technology
SIXT
Technology
SIXT
+0,58%
3 587,83
+20,86
+0,58%
—3 566,973 549,543 603,173 543,40——
SIXU
Utilities
SIXU
Utilities
SIXU
+0,69%
905,45
+6,18
+0,69%
—899,27900,59907,65897,62——
SIXV
Health care
SIXV
Health care
SIXV
+0,67%
1 495,35
+9,86
+0,67%
—1 485,471 483,471 496,001 472,99——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,92%
2 405,10
+22,04
+0,92%
—2 383,062 381,252 408,622 360,53——
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
23,97 US$
+2,57%
(+0,60) 1D
21 მაი, 14:55:20 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RARE...
Open
23,42 US$
High
24,12 US$
Low
23,10 US$
Mkt. cap
2,35 მლრდ.
Avg. vol.
1,70 მლნ.
Volume
690,34 ათ.
52-wk high
42,37 US$
52-wk low
18,29 US$
EPS
-6,10 US$
Beta
0,39
Shares outstanding
98,49 მლნ.
No. of employees
1 ათ.
News stories
From sources across the web
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOემილ კაკისი
Employees1,37 ათ.
Founded2010
HeadquartersNovato, კალიფორნია, ამერიკის შეერთებული შტატები
Sector-
Websiteultragenyx.com
Last report
5 მაი. 2026
Fiscal Period
Q1 2026
EPS / Est. (USD)
-1,54 US$ / -1,39 US$
-10,94%miss
Revenue / Est. (USD)
136,00 მლნ. / 157,93 მლნ.
-13,89%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
ივნ. 2025
სექ. 2025
დეკ. 2025
მარ. 2026
Revenue
166,50 მლნ.
159,93 მლნ.
207,28 მლნ.
136,00 მლნ.
Cost of goods sold
187,74 მლნ.
244,20 მლნ.
232,62 მლნ.
173,00 მლნ.
Cost of revenue
187,74 მლნ.
244,20 მლნ.
232,62 მლნ.
173,00 მლნ.
Research and development expenses
-
-
-
16,00 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
86,65 მლნ.
86,62 მლნ.
87,94 მლნ.
86,00 მლნ.
Operating expense
86,65 მლნ.
86,62 მლნ.
87,94 მლნ.
102,00 მლნ.
Total operating expenses
274,38 მლნ.
330,82 მლნ.
320,56 მლნ.
275,00 მლნ.
Operating income
-107,89 მლნ.
-170,89 მლნ.
-113,28 მლნ.
-139,00 მლნ.
Other non operating income
2,14 მლნ.
-1,04 მლნ.
-934,00 ათ.
-
EBT including unusual items
-114,00 მლნ.
-179,54 მლნ.
-127,69 მლნ.
-184,00 მლნ.
EBT excluding unusual items
-114,00 მლნ.
-180,22 მლნ.
-127,17 მლნ.
-154,00 მლნ.
Income tax expense
947,00 ათ.
873,00 ათ.
870,00 ათ.
1,00 მლნ.
Effective tax rate
-0,83%
-0,49%
-0,68%
-0,54%
Other operating expenses
-
-
-
-
Net income
-114,95 მლნ.
-180,41 მლნ.
-128,56 მლნ.
-185,00 მლნ.
Net profit margin
-69,04%
-112,81%
-62,02%
-136,03%
Earnings per share
-1,17
-1,81
-1,29
-1,54
Interest and investment income
5,79 მლნ.
5,86 მლნ.
6,51 მლნ.
6,00 მლნ.
Interest expense
-14,04 მლნ.
-14,15 მლნ.
-19,47 მლნ.
-21,00 მლნ.
Net interest expenses
-8,25 მლნ.
-8,28 მლნ.
-12,96 მლნ.
-15,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-99,27 მლნ.
-162,28 მლნ.
-104,50 მლნ.
-131,00 მლნ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer